Patent US2318721A successfully refreshed from Google Patents.
US5318780A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Medical uses of in situ formed gels
Assignee: MDV Technologies Inc
•
Filing: 1991-10-30
•
Granted: 1994-06-07
•
Expires: 2011-10-30
Abstract
Abstract Balanced pH, hyperosmotic, hypoosmotic, or isoosmotic gels are ideal vehicles for drug delivery. They are especially suited for topical body cavity or injection application of drugs or diagnostic agents; for drug or diagnostic agent delivery to the eye of a mammal; as protective corneal shields; or as ablatable corneal masks useful in laser reprofiling of the cornea. The compositions without the addition of a drug or diagnostic agent are useful as medical devices, for instance, in separating surgically or otherwise injured tissue as a means of preventing adhesions.
Inventors
- 👤 Tacey X. Viegas
- 👤 Lorraine E. Reeve
- 👤 Raymond L. Henry
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:31
CPC Classifications
A; A61; A61L; A61L31/00; A61L31/14; A61L31/16; A61F; A61F9/00; A61F9/007; A61F9/008; A61F9/00802; A61F9/00817; A61F9/00819; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61L15/00; A61L15/16; A61L15/22; A61L15/225; A61L15/42; A61L15/44; A61L24/00; A61L24/001; A61L24/0015; A61L24/0031; A61L24/04; A61L24/043; A61L27/00; A61L27/14; A61L27/26; A61L27/50; A61L27/52; A61L27/54; A61L31/04; A61L31/041; A61F2009/00861; A61F2009/00872; A61L2300/00; A61L2430/00; A61L2430/16; Y; Y10; Y10S; Y10S623/00; Y10S623/902; Y10S623/905
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
163 words
A process for the use of a composition as a medical device, for drug delivery, the application of a diagnostic agent, or the prevention of post operative adhesions, said process comprising (1) topically administering to a mammal an aqueous liquid vehicle which is capable of being gelled in situ to produce a hypo-osmotic, hyperosmotic, or iso-osmotic gel, and (2) gelling in situ said aqueous liquid vehicle to produce the hypo-osmotic, hyperosmotic, or iso-osmotic gel, wherein said aqueous liquid vehicle contains (a) about 0.2 to about 3.0 percent of at least one ionic polysaccharide, (b) about 1.0 to about 40 percent of at least one film forming polymer, (c) about 0.1 to 40 percent of a medicament or pharmaceutical, (d) water, and (e), optionally, a counter-ion capable of gelling said ionic polysaccharide, wherein percentages are by weight and are based on the total weight of the medicament or pharmaceutical, the film forming polymer, the ionic polysaccharide, and the water in the aqueous liquid vehicle.
Claim 2
Dependent Claim
163 words
A process for the use of a composition as a medical device, for drug delivery, the application of a diagnostic agent, or the prevention of post operative adhesions, said process comprising (1) topically administering to a mammal an aqueous liquid vehicle which is capable of being gelled in situ to produce a hypo-osmotic, hyperosmotic, or iso-osmotic gel, and (2) gelling in situ said aqueous liquid vehicle to produce the hypo-osmotic, hyperosmotic, or iso-osmotic gel, wherein said aqueous liquid vehicle contains (a) about 0.2 to about 3.0 percent of at least one ionic polysaccharide, (b) about 1.0 to about 40 percent of at least one film forming polymer, (c) about 0.1 to 40 percent of a medicament or pharmaceutical, (d) water, and (e), optionally, a counter-ion capable of gelling said ionic polysaccharide, wherein percentages are by weight and are based on the total weight of the medicament or pharmaceutical, the film forming polymer, the ionic polysaccharide, and the water in the aqueous liquid vehicle.
Claim 3
Dependent Claim
64 words
The process of claim 1 which comprises the application of said aqueous liquid vehicle as a two part composition comprising: part A) an aqueous liquid comprising at least one ionic polysaccharide and part B) an aqueous liquid solution containing a counter-ion capable of gelling said ionic polysaccharide, wherein combining parts A and B results in conversion of said aqueous liquid to an aqueous gel.
Claim 4
Dependent Claim
164 words
A process for the use of a composition as a medical device, for drug delivery, the application of a diagnostic agent, or the prevention of post operative adhesions, said process comprising (1) administering by injection to a mammal an aqueous liquid vehicle which is capable of being gelled in situ to produce a hypo-osmotic, hyperosmotic, or iso-osmotic gel, and (2) gelling in situ said aqueous liquid vehicle to produce a hypo-osmotic, hyperosmotic, or iso-osmotic gel, wherein said aqueous liquid vehicle contains (a) about 0.2 to about 3.0 percent of at least one ionic polysaccharide, (b) about 1.0 to about 40 percent of at least one film forming polymer, (c) about 0.1 to 40 percent of a medicament or pharmaceutical, (d) water, and (e), optionally, a counter-ion capable of gelling said ionic polysaccharide, wherein percentages are by weight and are based on the total weight of the medicament or pharmaceutical, the film forming polymer, the ionic polysaccharide, and the water in the aqueous liquid vehicle.
Claim 5
Dependent Claim
164 words
A process for the use of a composition as a medical device, for drug delivery, the application of a diagnostic agent, or the prevention of post operative adhesions, said process comprising (1) administering by injection to a mammal an aqueous liquid vehicle which is capable of being gelled in situ to produce a hypo-osmotic, hyperosmotic, or iso-osmotic gel, and (2) gelling in situ said aqueous liquid vehicle to produce a hypo-osmotic, hyperosmotic, or iso-osmotic gel, wherein said aqueous liquid vehicle contains (a) about 0.2 to about 3.0 percent of at least one ionic polysaccharide, (b) about 1.0 to about 40 percent of at least one film forming polymer, (c) about 0.1 to 40 percent of a medicament or pharmaceutical, (d) water, and (e), optionally, a counter-ion capable of gelling said ionic polysaccharide, wherein percentages are by weight and are based on the total weight of the medicament or pharmaceutical, the film forming polymer, the ionic polysaccharide, and the water in the aqueous liquid vehicle.
Claim 6
Dependent Claim
64 words
The process of claim 3 which comprises the application of said aqueous liquid vehicle as a two part composition comprising: part A) an aqueous liquid comprising at least one ionic polysaccharide and part B) an aqueous liquid solution containing a counter-ion capable of gelling said ionic polysaccharide, wherein combining parts A and B results in conversion of said aqueous liquid to an aqueous gel.
Claim 7
Dependent Claim
166 words
A process for the use of a composition as a medical device, for drug delivery, the application of a diagnostic agent, or the prevention of post operative adhesions, said process comprising (1) administering to a body cavity of a mammal an aqueous liquid vehicle which is capable of being gelled in situ to produce a hypo-osmotic, hyperosmotic, or iso-osmotic gel, and (2) gelling in situ said aqueous liquid vehicle to produce a hypo-osmotic, hyperosmotic, or iso-osmotic gel, wherein said aqueous liquid vehicle contains (a) about 0.2 to about 3.0 percent of at least one ionic polysaccharide, (b) about 1.0 to about 40 percent of at least one film forming polymer, (c) about 0.1 to 40 percent of a medicament or pharmaceutical, (d) water, and (e), optionally, a counter-ion capable of gelling said ionic polysaccharide, wherein percentages are by weight and are based on the total weight of the medicament or pharmaceutical, the film forming polymer, the ionic polysaccharide, and the water in the aqueous liquid vehicle.
Claim 8
Dependent Claim
166 words
A process for the use of a composition as a medical device, for drug delivery, the application of a diagnostic agent, or the prevention of post operative adhesions, said process comprising (1) administering to a body cavity of a mammal an aqueous liquid vehicle which is capable of being gelled in situ to produce a hypo-osmotic, hyperosmotic, or iso-osmotic gel, and (2) gelling in situ said aqueous liquid vehicle to produce a hypo-osmotic, hyperosmotic, or iso-osmotic gel, wherein said aqueous liquid vehicle contains (a) about 0.2 to about 3.0 percent of at least one ionic polysaccharide, (b) about 1.0 to about 40 percent of at least one film forming polymer, (c) about 0.1 to 40 percent of a medicament or pharmaceutical, (d) water, and (e), optionally, a counter-ion capable of gelling said ionic polysaccharide, wherein percentages are by weight and are based on the total weight of the medicament or pharmaceutical, the film forming polymer, the ionic polysaccharide, and the water in the aqueous liquid vehicle.
Claim 9
Dependent Claim
64 words
The process of claim 5 which comprises the application of said aqueous liquid vehicle as a two part composition comprising: part A) an aqueous liquid comprising at least one ionic polysaccharide and part B) an aqueous liquid solution containing a counter-ion capable of gelling said ionic polysaccharide, wherein combining parts A and B results in conversion of said aqueous liquid to an aqueous gel.
Claim 10
Dependent Claim
15 words
A process as defined in claim 1, wherein the counter-ion is present in latent form.
Claim 11
Dependent Claim
15 words
A process as defined in claim 3, wherein the counter-ion is present in latent form.
Claim 12
Dependent Claim
15 words
A process as defined in claim 5, wherein the counter-ion is present in latent form.
References Cited (Backward Citations)
US4188373A
Cited
US4570626A
Cited
US4861760A
Cited
US4856513A
Cited
US4911926A
Cited
US4948575A
Cited
EP0386960A2
Cited
US5071644A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-06-06 | 1997-12-06 | 1998-06-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-06-06 | 2001-12-06 | 2002-06-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-06-06 | 2005-12-06 | 2006-06-07 | $7700.00 | Window Closed / Lapsed |